Abstract: The invention relates generally to recombinant sialidases, methods and compositions for extending the serum half-life of the recombinant sialidases, and use of the same in the treatment of a sialic acid-related disorder.

Abstract: The present application provides compositions and methods for treating a patient with cancer, and in particular epithelial tumors and carcinomas, with antibodies directed to CD33-like Siglecs.

Abstract: Described herein are systems, method and devices for modulating the cholinergic anti-inflammatory pathway. The systems described herein may include one or more implantable leads configured to be used to stimulate the inflammatory reflex. These leads typically include a flexible body region, a plurality of electrodes (or contacts) and may be used with a stylet or other inserter. The leads may also include one or more anchors. Exemplary leads may be intra-carotid sheath field-effect leads (“sheath FE” leads), carotid sheath cuff leads (“sheath cuff” leads), intracardiac leads, vagus nerve cuff leads (“vagus cuff” leads), and intravenous leads (“intravascular” leads). Leads (e.g., intravascular leads) may be chronic or acute.